Kathryn Lindsay Ball

Title: Kathryn Lindsay Ball: Innovator in Cancer Research

Introduction

Kathryn Lindsay Ball is a prominent inventor based in Dundee, GB. She has made significant contributions to the field of cancer research through her innovative work on Cdk4 activity inhibition. Her research focuses on developing therapeutic methods to combat tumors and hyperproliferative disorders.

Latest Patents

Kathryn holds a patent titled "Methods and means for inhibition of Cdk4 activity." This patent describes how peptide fragments of p21 can inhibit the interaction between cyclin D1 and Cdk4, thereby affecting Cdk4 activity. The peptides, derivative peptides, and non-peptidyl mimetics are useful in modulating Cdk4 activity, which is crucial for processes like RB phosphorylation and cellular proliferation. This innovation indicates potential therapeutic applications in treating tumors and other hyperproliferative disorders.

Career Highlights

Kathryn is associated with Cyclacel Limited, a company dedicated to advancing cancer therapies. Her work has been instrumental in developing new strategies for cancer treatment, showcasing her commitment to improving patient outcomes through scientific innovation.

Collaborations

Kathryn collaborates with notable professionals in her field, including David Philip Lane, enhancing the impact of her research through shared expertise and knowledge.

Conclusion

Kathryn Lindsay Ball's contributions to cancer research through her innovative patents and collaborations highlight her role as a leading inventor in the scientific community. Her work continues to pave the way for advancements in therapeutic strategies against cancer.